Research compendium

Cotadutide

Cotadutide is a peptide GLP-1/glucagon agonist studied through metabolic, liver and kidney endpoints. Its literature distinguishes biomarker change from long-term clinical outcomes. Measurements across organs do not make a trial general proof of multi-organ protection.

This is a research reference, not a product offered in the Asciende catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.

What is established and what remains a hypothesis

Keep source limits and editorial status visible. A proposed mechanism should not be presented as a confirmed property in every context.

Is the source the original work, a review or a later interpretation?
Has the observation been reproduced under independent conditions?
Does the material defined in the paper match the entity named in this entry?

Find readings for this question

Mechanism described in the literature

The molecule combines agonism at two receptors. The cited clinical designs observe that combined pharmacology without assigning each change exclusively to GLP-1 or glucagon.

Classification

Dual GLP-1 and glucagon receptor agonist peptide

Other names

Cotadutide

What the liver data establish

The fifty-four-week study enrolled adults with overweight or obesity and type 2 diabetes. Initial primary endpoints were HbA1c and weight. Liver analyses used enzymes and noninvasive indices, including exploratory analyses. Observed liver-parameter changes are not biopsy-demonstrated fibrosis reversal.

What the kidney trial measured

In adults with type 2 diabetes and chronic kidney disease, some cotadutide groups showed lower urinary albumin-to-creatinine ratios than placebo. The primary endpoint concerned albuminuria and follow-up was limited. This did not demonstrate prevention of long-term kidney failure.

Why endpoint hierarchy matters

A biomarker can justify further research without resolving the broader clinical question. Separate primary results, exploratory analyses and outcomes never measured. This prevents a plausible hypothesis from being presented as a confirmed conclusion.

Questions and answers

Does albuminuria represent complete kidney function?

No. It is a specific measurement, not every component of kidney function or future events.

Do liver indices replace a biopsy?

Not automatically. Each method has a purpose, and the conclusion must match the measurement actually performed.